Cite This Page

Jump to: navigation, search

Bibliographic details for Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies

Citation styles for Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies

APA style

Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies. (2024, January 17). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 00:18, May 14, 2024 from https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427.

MLA style

"Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 17 Jan 2024, 08:34 UTC. 14 May 2024, 00:18 <https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 17 January 2024, 08:34 UTC, <https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427> [accessed 14 May 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427 (accessed May 14, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 17, 08:34 UTC [cited 2024 May 14]. Available from: https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427.

Bluebook style

Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies, https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427 (last visited May 14, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427",
   note = "[Online; accessed 14-May-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred: 

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Phase_I_Pharmacogenomic_Substance_Conversation_Research_involving_Sorafenib_and_also_Bevacizumab_together_with_Paclitaxel_throughout_People_with_Advanced_Refractory_Strong_Malignancies&oldid=549427}",
   note = "[Online; accessed 14-May-2024]"
 }


Retrieved from "https://news.npo.digital/index.php?title=Special:CiteThisPage"